Sorrento Therapeutics. has filed a patent for a method of treating pulmonary inflammatory disease by neural ablation methods. The method involves ablating specific nerves in the subject’s body using chemical or radiofrequency ablation. This could potentially interrupt the neurogenic inflammatory process occurring in the lungs. GlobalData’s report on Sorrento Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Sorrento Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Sorrento Therapeutics, Personalized cancer vaccines was a key innovation area identified from patents. Sorrento Therapeutics's grant share as of September 2023 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230301700A1) describes a method for treating pulmonary inflammatory disease and interrupting a neurogenic inflammatory process in the lungs. The method involves ablating certain nerves or ganglia in the subject using chemical ablation or radiofrequency ablation.

The patent claims specify various options for the nerves or ganglia that can be ablated, including the vagal nerve, stellate ganglion, dorsal horn of the spinal cord, or thoracic dorsal root ganglion. The ablation can be performed using either chemical ablation or radiofrequency ablation.

In the case of radiofrequency ablation, the patent claims mention the use of alternating current with a frequency of about 350-500 kHz. For chemical ablation, the patent claims suggest administering a neurolytic agent epidurally, peri-ganglionically, intra-ganglionically, or by local infiltration. Examples of neurolytic agents mentioned in the claims include phenol, chlorocresol, ethanol, glycerol, hypertonic saline, and neurotoxins.

The patent claims also cover various administration methods, including epidural administration, peri-ganglionic nerve block, intra-ganglionic administration, and local infiltration. The neurolytic agent can be administered in a pharmaceutical formulation with a pharmaceutically acceptable carrier.

The pulmonary inflammatory diseases that can be treated using this method include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH), chronic inflammatory lung disease, pulmonary fibrosis, pulmonary vasculitis, pulmonary sarcoidosis, lung transplantation-related inflammation and/or infection, bronchitis, sinusitis, asthma, cystic fibrosis, bacterial, fungal, parasite, or viral infections, bronchiolitis obliterans syndrome (BOS), primary ciliary dyskinesia (PCD), alveolar proteinosis, idiopathic pulmonary fibrosis (IPF), eosinophilic pneumonia, eosinophilic bronchitis, inflammation and/or infection associated with mechanical ventilation or ventilator-associated pneumonia, asbestos-related airway disorders or diseases, dust-related airway disorders or diseases, silicosis, and radiation or chemical agent-related airway diseases or disorders.

The patent claims also specifically mention the association of pulmonary inflammatory diseases with viral pneumonia, influenza, and coronavirus infections, including COVID-19.

Additionally, the patent claims describe the possibility of ablating afferent nerves in the thoracic dorsal root ganglion to support palliative ventilation therapy. The method can be administered as a single dose or periodically.

The patent claims also cover the use of a neurolytic agent or radiofrequency source for the manufacture of a medicament for use in the described method.

Overall, this patent describes a method for treating pulmonary inflammatory diseases and interrupting neurogenic inflammatory processes in the lungs by ablating specific nerves or ganglia using chemical or radiofrequency ablation techniques. The method offers potential treatment options for a wide range of pulmonary inflammatory diseases, including those associated with viral infections such as COVID-19.

To know more about GlobalData’s detailed insights on Sorrento Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies